Cardiometabolic diseases are a cluster of interconnected conditions involving the heart, blood vessels, kidneys, and the body’s metabolic machinery. The most familiar members of the group include heart disease, type 2 diabetes, obesity, and chronic kidney disease, but the concept extends to conditions like fatty liver disease, metabolic syndrome, and the specific blood-fat abnormalities that accelerate artery damage. What makes them “cardiometabolic” rather than separate diagnoses is the recognition that they share root causes, feed into one another, and tend to travel together in the same person. The American Heart Association now frames this overlap as a syndrome in its own right, with excess body fat, insulin resistance, and chronic inflammation acting as common soil from which multiple organ-level diseases grow.
Why These Diseases Are Grouped Together
For decades, a person with high blood pressure, high blood sugar, and early kidney trouble might see three different specialists who treated each problem in isolation. The shift toward a “cardiometabolic” framework reflects a growing understanding that these conditions share the same underlying biology and worsen each other in a loop. The American Heart Association formalized this in 2023 with a presidential advisory describing how metabolic risk factors, chronic kidney disease, and the cardiovascular system interact, noting that the most significant clinical consequence is a high rate of cardiovascular events and cardiovascular death.1PubMed. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association The AHA now classifies this interconnection into four stages based on how many risk factors and clinical signs are present, ranging from early excess body fat and metabolic risk all the way to established heart or kidney disease.2PubMed. An overview of cardiovascular-kidney-metabolic syndrome
The practical importance of this grouping is that treating one condition in isolation often fails if the shared drivers are ignored. Lowering blood sugar without addressing the insulin resistance and inflammation that also damage blood vessels and kidneys may slow one disease while the others quietly advance. A scientific statement from the AHA emphasizes that the confluence of metabolic risk factors and kidney disease within this syndrome is strongly linked to adverse cardiovascular and kidney outcomes.3PubMed. A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome
The Shared Engine of Damage
If there is one thread running through nearly every cardiometabolic disease, it is insulin resistance paired with chronic, low-grade inflammation. When cells stop responding normally to insulin, the body compensates by producing more of it. That extra insulin and the high blood sugar that eventually follows trigger a cascade: blood-fat levels shift in harmful directions, blood vessels stiffen, and inflammatory signals ramp up throughout the body. Research describes how altered insulin signaling promotes obesity, abnormal blood fats, inflammation, damage to blood vessel linings, and high blood pressure, all of which set the stage for artery-clogging atherosclerosis.4PubMed Central. Insulin resistance and cardiovascular disease
Visceral fat, the deep belly fat packed around organs, plays a particularly outsized role. Unlike the fat just under your skin, visceral fat actively secretes fatty acids and inflammatory molecules directly into the portal vein, which feeds straight into the liver. That flood of metabolic signals causes fat to build up in the liver, fuels body-wide insulin resistance, and ramps up inflammation and scarring.5PubMed Central. The pathophysiology of visceral adipose tissues in cardiometabolic diseases The liver, in turn, becomes a relay station: its dysfunction worsens the metabolic environment for every other organ.
Blood vessel linings take a beating in this environment. When exposed to high blood sugar, abnormal blood fats, and hormonal imbalances, the endothelium (the thin inner layer of arteries) starts to malfunction. It produces less nitric oxide, the molecule that keeps vessels relaxed and open, while pumping out inflammatory and vessel-constricting substances. This endothelial dysfunction has become recognized as a hallmark of cardiometabolic vascular damage and contributes to heart failure and other cardiovascular diseases.6PubMed Central. New Insights into Endothelial Dysfunction in Cardiometabolic Diseases: Potential Mechanisms and Clinical Implications Over time, artery walls accumulate collagen, lose their elastic fibers, and even calcify, making them stiffer and forcing the heart to work harder.7CardioMetabolic Syndrome Journal. Arterial Stiffness and Pulsatile Hemodynamics in Cardiometabolic Disorders
Blood Fats and How They Go Wrong
When people hear “high cholesterol,” they often think of one number, but the blood-fat picture in cardiometabolic disease is more nuanced. A pattern called atherogenic dyslipidemia is especially common: triglyceride levels climb, protective HDL cholesterol drops, and LDL particles shift toward a smaller, denser type that burrows more easily into artery walls. Each of these changes independently raises the risk of cardiovascular disease.8PubMed Central. Atherogenic dyslipidemia A large study tracking these specific lipid subfractions found that people in the highest category of triglyceride-rich lipoprotein cholesterol had roughly three times the risk of heart attack compared to those in the lowest category, while those with the highest levels of small, dense LDL had nearly four times the risk.9PubMed Central. Triglyceride-Rich Lipoprotein Cholesterol, Small Dense LDL Cholesterol, and Incident Cardiovascular Disease Standard cholesterol panels can miss this pattern if they report only total LDL without breaking it into particle subtypes.
The Liver as an Overlooked Player
One of the more significant recent additions to the cardiometabolic picture is the liver. Metabolic dysfunction-associated steatotic liver disease (MASLD, previously known as nonalcoholic fatty liver disease) is now recognized as far more than a liver problem. It shares the same root causes as the rest of the cardiometabolic family: insulin resistance, excess body fat, high blood pressure, and abnormal blood fats. Research increasingly identifies MASLD as a risk factor for cardiovascular disease that may be independent of those shared risk factors.10PubMed Central. Metabolic dysfunction-associated steatotic liver disease as a cardiovascular risk factor In other words, having a fatty liver may raise your heart risk above what your weight and blood sugar alone would predict.
A 2024 Circulation report noted that the overlap in disease processes and the parallel rise in prevalence of cardiovascular disease, metabolic syndrome, and MASLD highlight the multisystem consequences of poor metabolic health, including ectopic fat deposited in the tissue surrounding the heart itself.11PubMed. Cardiovascular-Liver-Metabolic Health: Recommendations in Screening, Diagnosis, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease A comprehensive evidence review concluded that the association between MASLD and coronary artery disease, atrial fibrillation, and heart failure appears not only synergistic but also independent of other known cardiovascular risk factors, highlighting it as a key cardiometabolic risk factor that deserves early attention.12PubMed Central. Cardiovascular Disease in the Context of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
How the Pancreas Gets Worn Down
The progression from metabolic risk to full-blown type 2 diabetes follows a pattern that also ratchets up cardiovascular danger. Under constant exposure to excess nutrients, the insulin-producing beta cells of the pancreas work overtime. Initially they compensate by cranking out more insulin, but this hypersecretion strains the cells’ internal machinery, eventually causing them to burn out. As beta-cell function declines, blood sugar control deteriorates, and the liver’s ability to clear harmful lipoproteins from the blood drops, further raising cardiovascular risk.13PubMed Central. β-Cell Dysfunction, Hepatic Lipid Metabolism, and Cardiovascular Health in Type 2 Diabetes
At the cellular level, overworked beta cells develop what amounts to an internal stress crisis. Their protein-folding machinery gets overwhelmed, their energy-producing mitochondria become dysfunctional, and toxic byproducts accumulate, eventually triggering cell death pathways.14JCI Insight. Cell dysfunction during progression of metabolic syndrome to type 2 diabetes This is not an overnight collapse but a slow grind over years, which is why the pre-diabetes window is both a danger zone and an opportunity for intervention.
Risk Factors Beyond the Usual Suspects
The traditional risk factors for cardiometabolic disease (poor diet, inactivity, smoking, excess weight) are well known. But several less obvious contributors deserve attention.
Ultra-processed foods have emerged as a consistent and specific risk factor. These are products that go well beyond simple processing: they are industrial formulations typically high in refined starches, added sugars, unhealthy fats, and additives. High consumption has been repeatedly linked to greater rates of obesity, insulin resistance, type 2 diabetes, abnormal blood fats, and high blood pressure.15PubMed. Ultra-Processed Foods and Cardiometabolic Health: A Review of Current Evidence The concern is not limited to adults. A study of children found that those eating the most ultra-processed foods had higher body mass, larger waist circumference, higher fasting blood sugar, and lower HDL cholesterol. Replacing just 100 grams of ultra-processed food per day with minimally processed alternatives was linked to lower BMI and fasting glucose.16JAMA Network Open. Ultraprocessed Food Consumption and Cardiometabolic Risk Factors in Children A large multinational cohort study found that each standard-deviation increase in ultra-processed food intake (roughly an extra 260 grams per day) was associated with about a 9% higher risk of developing both cancer and cardiometabolic diseases together. The association was strongest for animal-based ultra-processed products and artificially sweetened beverages, while ultra-processed breads and plant-based alternatives showed no clear link.17PubMed Central. Consumption of ultra-processed foods and risk of multimorbidity of cancer and cardiometabolic diseases
Sleep is another underappreciated factor. Even short-term sleep deprivation impairs insulin sensitivity and glucose tolerance, creating what resembles a pre-diabetic state. Over time, chronic insufficient sleep and sleep disorders like obstructive sleep apnea promote insulin resistance independently of other risk factors, elevating the risk of type 2 diabetes.18PubMed Central. Sleep and Cardiometabolic Health: A Narrative Review of Epidemiological Evidence, Mechanisms, and Interventions The AHA now recognizes circadian health as a contributor to cardiometabolic outcomes, noting that disruptions to the body’s 24-hour rhythms can adversely affect weight regulation, blood sugar control, blood pressure, and cardiovascular function.19PubMed. Role of Circadian Health in Cardiometabolic Health and Disease Risk Shift workers, frequent fliers, and people with irregular sleep schedules carry additional cardiometabolic risk for this reason.
The gut microbiome is a third less-obvious contributor. An imbalanced gut microbial community is associated with intestinal inflammation and a weakened gut barrier, which lets bacterial components and metabolites (including trimethylamine N-oxide, or TMAO) leak into the bloodstream, potentially promoting cardiovascular disease.20PubMed Central. Role of gut microbiota in cardiovascular diseases
Genetics, Lifestyle, and Whether You Can Outrun Your DNA
Genetics clearly matter. Family history of diabetes, heart disease, or kidney disease raises a person’s baseline risk. But a large cohort study offers some encouraging perspective: among people with a high genetic risk for heart disease, those who improved their cardiovascular health behaviors from middling to ideal cut their risk of ischemic heart disease in half compared to those who stayed at the same middling level.21PubMed Central. Changes in Cardiovascular Health, Genetic Risk, and Cardiometabolic Diseases Genetics loads the gun, as the saying goes, but lifestyle pulls the trigger. And the data suggest that even a loaded gun can often be kept on safety.
Roots in the Womb and Early Life
Cardiometabolic risk can begin before birth. Epidemiological studies have shown that an adverse environment in the uterus, such as exposure to malnutrition during pregnancy, is associated with an increased risk of cardiometabolic disease in adulthood. The idea, known as the developmental origins of health and disease hypothesis, holds that a fetus deprived of adequate nutrients makes survival-oriented metabolic adaptations. Those adaptations become harmful if the child is later born into an environment of caloric abundance. The mismatch between a thrifty prenatal setting and a nutrient-rich postnatal one may program the body for insulin resistance and fat storage through epigenetic changes, modifications that alter how genes behave without changing the DNA sequence itself.22PubMed Central. Fetal Growth and Intrauterine Epigenetic Programming of Obesity and Cardiometabolic Disease This means that some degree of cardiometabolic vulnerability can be “inherited” not through the genetic code, but through the conditions a person experienced in the earliest months of development.
Catching Trouble Early
One of the trickiest aspects of cardiometabolic disease is that the damage often builds silently. Blood pressure, blood sugar, and cholesterol can all drift into risky territory for years without producing symptoms. The AHA’s staging system was designed partly to flag people before they develop clinical disease: the earliest stage involves only excess body fat or mildly disordered metabolism, while overt disease shows up only at the later stages.
There is growing interest in whether standard screening cutoffs miss people already on a dangerous trajectory. A recent study found that markers of cardiometabolic disease start to climb when hemoglobin A1C (a measure of average blood sugar over a few months) crosses just 5.0%, well below the 5.7% threshold usually flagged as pre-diabetes. The proportion of patients showing at least one abnormal cardiometabolic marker rose from about 21% at an A1C of 5.0% to 50% at an A1C of 5.7%, with roughly 4% more patients crossing into abnormal territory for every tenth-of-a-percent rise in A1C within that supposedly normal range.23AACE Endocrinology and Diabetes. Cardiometabolic Disease–Associated Markers Begin to Increase at an A1C >5% The clinical implication: if your lab report says your blood sugar is “normal” but trending upward, the metabolic machinery may already be shifting.
New Medications Changing the Landscape
For a long time, treatment of cardiometabolic conditions meant separate pills for each problem: a statin for cholesterol, metformin for blood sugar, an ACE inhibitor for blood pressure. Two newer drug classes are reshaping this approach by addressing multiple cardiometabolic problems at once.
GLP-1 receptor agonists (drugs like semaglutide and tirzepatide, originally developed for diabetes) reduce risks of major adverse cardiovascular events such as heart attack, stroke, and cardiovascular death, and lower the risk of hospitalization for heart failure.24The Lancet. What Are Cardiometabolic Diseases? A meta-analysis of four large randomized trials involving nearly 20,000 obese or overweight patients with existing cardiovascular disease found that GLP-1 analogs reduced all-cause mortality by about 18%, shrank waist circumference substantially, lowered systolic blood pressure, and cut hospitalization for heart failure by more than half. They also significantly lowered C-reactive protein, a marker of body-wide inflammation.25PubMed. Cardiometabolic effects of GLP-1 analogs in obese and overweight patients with preexisting cardiovascular disease Semaglutide at a higher dose and the dual-acting tirzepatide have both shown reductions in cardiovascular mortality and heart failure symptoms along with greater weight loss and improvements in cardiometabolic conditions.26Medicina ClĂnica (English Edition). GLP-1 receptor agonists in obesity treatment: Effects on cardiometabolic variables and cardiovascular disease
SGLT2 inhibitors are the other class rewriting the playbook. Originally designed to lower blood sugar by making the kidneys excrete more glucose, they turned out to protect the heart and kidneys through mechanisms that go well beyond glucose control. These include improving how the kidneys handle sodium, dialing down overactive stress-hormone pathways, boosting red blood cell production, reducing uric acid levels, and shifting the body’s fuel use toward a state that resembles fasting.27PubMed. Mechanisms of heart failure and chronic kidney disease protection by SGLT2 inhibitors in nondiabetic conditions Their benefits in heart failure and chronic kidney disease hold even in people who do not have diabetes, which underscores how cardiometabolic diseases share biology that can be targeted across diagnoses.
An Evolutionary Mismatch
One way to understand why cardiometabolic diseases are so common is to zoom out to an evolutionary scale. For most of human history, food was scarce and physical exertion was constant. Bodies that were efficient at storing fat, conserving salt, and mounting quick inflammatory responses had a survival advantage. In modern environments of caloric abundance, sedentary work, and round-the-clock artificial light, those same traits become liabilities. Evolutionary mismatch theory frames this neatly: traits that once helped our ancestors survive now drive chronic disease in a world of surplus.28PubMed Central. The Evolutionary Misfit: Evolution, Epigenetics, and the Rise of Non-Communicable Diseases Atherosclerosis itself has been argued to be the long-term vascular consequence of biological systems that evolved under intermittent metabolic stress but now face chronic, unrelenting activation of those same pathways.29PubMed. Atherosclerosis as an evolutionary mismatch disease: from ancestral biology to cardiometabolic vulnerability We are, in a sense, running ancient hardware in a modern operating environment, and cardiometabolic disease is the system crash that results.
Exercise and the Molecules It Releases
Physical activity remains one of the most effective interventions across the entire cardiometabolic spectrum, and researchers are increasingly understanding why at a molecular level. During exercise, muscles release signaling molecules called myokines. One that has attracted particular attention is irisin, which appears to help regulate energy metabolism, protect blood vessels, and reduce oxidative stress and inflammatory signaling.30Wiley Online Library. Irisin, the Myokine: Guardian and Mediator in Cardiovascular System Exercise also directly improves insulin sensitivity, lowers blood pressure, shifts blood-fat profiles in a favorable direction, reduces visceral fat, and improves endothelial function. Its benefits hit nearly every mechanism described earlier in a single intervention, which is why regular physical activity is advocated as a cornerstone prevention strategy. It does not need to be extreme. Consistent moderate-intensity movement, the kind that raises your heart rate and makes conversation slightly harder, covers much of the benefit.
What makes the cardiometabolic framework genuinely useful, for patients and clinicians alike, is that it encourages thinking about the whole system. Rather than chasing one lab number at a time, the approach asks what is driving the metabolic environment that pushes multiple organs toward failure simultaneously. Whether the entry point is a rising A1C, a fatty liver finding on an ultrasound, a stubbornly high triglyceride level, or creeping blood pressure, the underlying question is the same: what combination of metabolic, inflammatory, and vascular dysfunction is at work, and how can it be interrupted before the next domino falls?